Generic Actos Launched by Mylan, Teva and Ranbaxy

Mylan, Teva and Ranbaxy announced on Friday that they have each launched generic forms of Takeda’s blockbuster type 2 diabetes drug Actos in the US. The generic drugmakers are sharing 180-day exclusivity for the generic versions of the branded medication, which receives in sales of roughly $2.7 billion a year across America. Actos (pioglitazone) is

Continue Reading

Amgen and Watson Pharmaceuticals Announce Cancer Biosimilars Agreement

Amgen, an US biotech major, is partnering with Watson Pharmaceuticals to develop and commercialise several oncology antibody biosimilars. The new partners commented that the partnership “reflects the shared belief that the development and commercialisation of biosimilar products will not follow a pure brand or generic model, and will require significant expertise, infrastructure, and investment to

Continue Reading